TRI- OG TETRACYCLISKE FORBINDELSER

Compounds of the general formula 1 where A is C1-10-alkylene; Y-Z is , -CH=CH-, -CH2CH2-, ; or the groups R1 are identical or different and are each hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, C1-6- alkylthio or cyano; groups R2 are identical or different and are each hydrogen, halogen, C1-6-alkyl,...

Full description

Saved in:
Bibliographic Details
Main Authors UNO HITOSHI, SATO FUMINORI, HATANO NAONOBU, KUROKAWA MIKIO
Format Patent
LanguageDanish
Published 09.04.1986
Edition4
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Compounds of the general formula 1 where A is C1-10-alkylene; Y-Z is , -CH=CH-, -CH2CH2-, ; or the groups R1 are identical or different and are each hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, C1-6- alkylthio or cyano; groups R2 are identical or different and are each hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio or cyano; and R3 is hydrogen, C1-6-alkyl or C1-6-alkoxy; R4 is phenyl, phenyl-C1-10-alkyl, where the alkyl moiety can optionally be substituted once by hydroxyl, phenyl-C3-5-alkenyl, diphenylmethyl, naphthyl, thiazolyl, pyridyl which is optionally substituted by C1- 6-alkoxycarbonyl, pyrimidyl which is optionally substituted by C1-6-alkyl, quinolyl, benzoyl-C1-5-alkyl, benzoyl, furoyl, thienoyl, phenyloxycarbonyl, phenyloxysulphonyl or phenylsulphonyl; a is 2 or 3, b and c are each 1 or 2, and d is an integer from 0 to 2, with the proviso that phenyl and phenyl moieties and naphthyl moieties in the abovementioned definition may optionally be substituted by one or two groups selected from the class consisting of halogen, hydroxyl, nitro, C1-6-alkyl, trifluoromethyl and C1-6-alkoxy, and, if two substituents are present, they can be identical or different, and pharmaceutically acceptable salts thereof, a process for preparing the compound, and pharmaceutical preparations which comprise the compound. The compounds and their salts exhibit a potent calcium antagonist effect and can be used for the prophylaxis and treatment of hypertension and/or ischaemic heart disease.
Bibliography:Application Number: DK19860001606